EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial–Mesenchymal Transition and Metastasis

Yueh-Shan Weng, I-Tsang Chiang, Jai-Jen Tsai, Yu-Chang Liu, Fei-Ting Hsu

International Journal of Radiation Oncology*Biology*Physics · 2023-03 · 115 (3) · 719-732

DOI: 10.1016/j.ijrobp.2022.09.060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023-03. Verfasst von Yueh-Shan Weng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Science and Technology, China Medical University, Taichung 406, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study suggested that lenvatinib may incapacitate hepatocellular carcinoma (HCC) to radiation treatment by abrogating radiation-induced Src/signal transducer and the activator of transcription 3 signaling (STAT3)/nuclear factor-κB (NF-κB) to escalate radiation-induced extrinsic and intrinsic apoptosis. These findings uncover the role of targeting Src and its arbitrating epithelial-mesenchymal transition (EMT), which could increase the anti-HCC efficacy of radiation therapy (RT). Lenvatinib and sorafenib are multikinase inhibitors used to treat HCC. Lenvatinib is noninferior to sorafenib in the therapeutic response in HCC. However, whether lenvatinib intensifies the anti-HCC efficacy of RT is ambiguous. Several oncogenic kinases and transcription factors, such as Src, STAT3, and NF-κB, enhance the radiosensitivity of cancers. Therefore, we aimed to investigate the roles of the Src/STAT3/NF-κB axis in HCC after RT treatment and assessed whether targeting Src by lenvatinib may enhance the effectiveness of RT. METHODS AND MATERIALS: Hep3B, Huh7, HepG2, and SK-Hep1 HCC cells and 2 types of animal models were used to identify the efficacy of RT combined with lenvatinib. Cellular toxicity, apoptosis, DNA damage, EMT/metastasis regulation, and treatment efficacy were validated by colony formation, flow cytometry, Western blotting, and in vivo experiments, respectively. Knockdown of Src by siRNA was also used to validate the role of Src in RT treatment. RESULTS: Silencing Src reduced STAT3/NF-κB signaling and sensitized HCC to radiation. Lenvatinib reversed radiation-elicited Src/STAT3/NF-κB signaling while enhancing the anti-HCC efficacy of radiation. Both lenvatinib and siSrc promoted the radiation effect of cell proliferation on suppression, inhibition of the invasion ability, and induction of apoptosis in HCC. Lenvatinib also alleviated radiation-triggered oncogenic and EMT-related protein expression. CONCLUSIONS: Our findings uncovered the role of the Src/STAT3/NF-κB regulatory axis in response to radiation-induced toxicity and confirmed Src as the key regulatory molecule for radiosensitization of HCC evoked by lenvatinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAnimalsNF-kappa BSorafenibEpithelial-Mesenchymal TransitionNegotiatingApoptosisCell Line, TumorSTAT3 Transcription FactorPhenylurea CompoundsQuinolines

Substanzen

NF-kappa BSorafenibSTAT3 Transcription FactorlenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Department of Biological Science and Technology, China Medical University, Taichung 406, Taiwan.
  • Department of Radiation Oncology, Show Chwan Memorial Hospital, Changhua 500, Taiwan; Department of Radiation Oncology, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan; Department of Medical Imaging and Radiol…
  • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Yuan-Shan/Su-Ao Branch, Yi-Lan 260, Taiwan; Department of Medicine/Medical Research and Education, Taipei Veterans General Hospital…
  • Department of Radiation Oncology, Show Chwan Memorial Hospital, Changhua 500, Taiwan; Department of Medical Imaging and Radiologic Sciences, Central Taiwan University of Science and Technology, Taichung 406, Taiwan; Dep…
  • Department of Biological Science and Technology, China Medical University, Taichung 406, Taiwan. Electronic address: sakiro920@gmail.com.

Förderung

  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Weng, Y. S., Chiang, I. T., Tsai, J. J., Liu, Y. C., & Hsu, F. T. (2023). Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial–Mesenchymal Transition and Metastasis. International Journal of Radiation Oncology*Biology*Physics, 115(3), 719-732. https://doi.org/10.1016/j.ijrobp.2022.09.060

Vancouver

Weng YS, Chiang IT, Tsai JJ, Liu YC, Hsu FT. Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial–Mesenchymal Transition and Metastasis. International Journal of Radiation Oncology*Biology*Physics. 2023;115(3):719-732. doi:10.1016/j.ijrobp.2022.09.060

BibTeX
@article{Weng2023,
  author = {Weng, Yueh-Shan and Chiang, I-Tsang and Tsai, Jai-Jen and Liu, Yu-Chang and Hsu, Fei-Ting},
  title = {Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial–Mesenchymal Transition and Metastasis},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2023},
  volume = {115},
  number = {3},
  pages = {719--732},
  doi = {10.1016/j.ijrobp.2022.09.060}
}
Kostenlos starten →